Canadian Study of Prediction of Risk and Evolution to Dialysis, Death and Interim Cardiovascular Events Over Time (CanPREDDICT)

November 27, 2013 updated by: University of British Columbia

CanPREDDICT: Canadian Study of Prediction of Risk and Evolution to Dialysis, Death and Interim Cardiovascular Events Over Time

This study will follow 2500 prevalent Chronic Kidney Disease (CKD) patients with Glomerular Filtration Rate (GFR) from 15-45 ml/min for 30 months with serial measurements every 6 months and subsequent annual chart review up to 60 months. This observational study will analyze the demographics, clinical status, medications and blood and urine samples of these patients and study the conventional biochemical, hormonal and metabolic parameters assessing which underlying biomarkers reflect the processes involved with disease progression.

Study Overview

Status

Unknown

Conditions

Study Type

Observational

Enrollment (Actual)

2602

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Canada
    • Alberta
      • Calgary, Alberta, Canada
        • Foothills Hospital
      • Edmonton, Alberta, Canada
        • University of Alberta
    • British Columbia
      • Penticton, British Columbia, Canada
        • Penticton Regional Hospital
      • Vancouver, British Columbia, Canada
        • Vancouver General Hospital
      • Vancouver, British Columbia, Canada
        • BC Children's Hospital
      • Vancouver, British Columbia, Canada
        • St. Paul's Hospital
    • Manitoba
      • Winnipeg, Manitoba, Canada
        • St. Boniface Hospital
    • Newfoundland and Labrador
      • St John's, Newfoundland and Labrador, Canada
        • Eastern Regional Health Authority, Health Sciences Centre
    • Nova Scotia
      • Halifax, Nova Scotia, Canada
        • QEII Health Sciences Centre
      • Sydney, Nova Scotia, Canada
        • Cape Breton District Health Authority
    • Ontario
      • Hamilton, Ontario, Canada
        • St Joseph's Hospital
      • Kingston, Ontario, Canada
        • Kingston General Hospital
      • London, Ontario, Canada
        • London Health Science Centre- Victoria Campus
      • London, Ontario, Canada
        • London Health Science Centre- University Campus
      • Oak Ridges, Ontario, Canada
        • York Central
      • Ottawa, Ontario, Canada
        • University of Ottawa
      • Timmins, Ontario, Canada
        • Timmins & District Hospital
      • Toronto, Ontario, Canada
        • St. Michael's Hospital
      • Toronto, Ontario, Canada
        • University Health Network
      • Toronto, Ontario, Canada
        • Sunnybrook Hospital
    • Quebec
      • Greenfield Park, Quebec, Canada
        • Charles Le Moyne Hospital
      • Montreal, Quebec, Canada
        • Royal Victoria Hospital
      • Montreal, Quebec, Canada
        • Hopital du Sacre-Coeur
      • Montréal, Quebec, Canada
        • Maisonneuve-Rosemont Hopital
      • Quebec City, Quebec, Canada
        • CHUQ: L'Hôtel-Dieu de Québec

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

19 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Nephrology Clinics across Canada

Description

Inclusion Criteria:

  • Patients currently seen by a nephrologist, or referred for evaluation of CKD
  • GFR between 15-45 ml/min
  • Adults 19 years (depending on age of consent in province) or older
  • At pediatric sites study participants will be eligible to participate at age 15 or older

Exclusion Criteria:

  • Organ transplant recipient
  • Life expectancy less than 12 months
  • Acute Vasculitis
  • Bioimpedance sub-study exclusion criteria:
  • Amputation (readings are inaccurate)
  • Any battery operated or electronic implanted device (such as pacemaker or implanted defibrillator - potential electrical hazard)
  • Pregnant women

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Bioimpedance sub-study cohort
Funded by a grant from Kidney Foundation of Canada, Dr. Catherine Clase initiated a bioimpedance sub-study across 7 centres and recruited n=416 within the CANPREDDICT population. The study uses bioimpedance measurements to assess volume status to determine the multivariable relationship between baseline volume overload and subsequent cardiovascular events. Subjects are followed at 6 months intervals for 2 years.
Ethnic enrichment cohort
Additional recruitment initiated and funded by the Principal Investigator, Adeera Levin for enriching the ethnic representation within the Canadian cohort on South Asian and Oriental Asian was completed from Sept 2012 to June 2013, n=53.
Original CanPreddict cohort
The original CanPreddict cohort was recruited from Jun 2008 - Oct 2009 has 2544 CKD patients across Canada.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Renal Replacement Therapy
Time Frame: 6 monthly for 3 years, annually up to 5 years
Renal Replacement Therapy is defined as dialysis start or transplantation.
6 monthly for 3 years, annually up to 5 years
Cardiovascular events
Time Frame: 6 monthly for 3 years, annually up to 5 years
Cardiovascular events are defined as myocardial infarction, ischemic and hemorrhagic stroke, coronary revascularization, congestive heart failure, peripheral bypass and gangrenes, adjudicated by a nephrologist, cardiologist and neurologist.
6 monthly for 3 years, annually up to 5 years
Death
Time Frame: 6 monthly for 3 years, annually up to 5 years
Deaths are reported with source documentation and adjudicated for ischemic or congestive cardiovascular death, other cardiovascular death, non-cardiovascular death and unknown cause of death.
6 monthly for 3 years, annually up to 5 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of British Columbia

Investigators

  • Principal Investigator: Adeera Levin, University of British Columbia

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

June 1, 2008

Primary Completion (Anticipated)

December 1, 2014

Study Completion (Anticipated)

December 1, 2014

Study Registration Dates

First Submitted

January 20, 2009

First Submitted That Met QC Criteria

January 21, 2009

First Posted (Estimate)

January 22, 2009

Study Record Updates

Last Update Posted (Estimate)

November 28, 2013

Last Update Submitted That Met QC Criteria

November 27, 2013

Last Verified

November 1, 2013

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • H07-02457

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Chronic Kidney Disease

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ecuador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe